BRAF and melanoma: In this report, we demonstrate that melanoma cells that either harbor activating NRAS mutations with BRAFWT or harbor the BRAFV600E mutation with wild-type NRAS, the BRAF is bound by HSP90 and under certain conditions is subject to degradation by HSP90 inhibition with 17-AAG.